Caricamento...
Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries
PURPOSE: Novel parenteral (bortezomib) and oral (lenalidomide) therapies have improved survival in myeloma, but the standard Medicare benefit covers only parenteral drugs. We examined the association between prescription drug coverage, receipt of therapy, and survival among Medicare beneficiaries wi...
Salvato in:
| Pubblicato in: | J Clin Oncol |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
American Society of Clinical Oncology
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6366642/ https://ncbi.nlm.nih.gov/pubmed/30113885 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2018.77.8894 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|